Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.00%
)
US TECH 100
28,308.00
(
-1.68%
)
Dow Jones
50,063.46
(
0.00%
)
Brent Oil
105.36
(
1.13%
)
Bitcoin
80,100.63
(
-1.18%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: poorgradstudent post# 57470

Saturday, 03/13/2010 1:59:32 AM

Saturday, March 13, 2010 1:59:32 AM

Post# of 257566
(MRK) This analyst is not exactly going out on a limb:

http://finance.yahoo.com/news/Analyst-Mercks-Vytorin-sales-apf-3357123240.html?x=0&.v=4

Sales of Merck & Co.'s blockbuster cholesterol drug Vytorin likely will continue to fall amid rising competition from rival brands and generic versions in the same class of pills, [Bernstein] analyst [Tim Anderson] predicted Friday.

LOL


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today